MYGN
MYRIAD GENETICS INC
Nasdaq In Vitro & In Vivo Diagnostic Substances Accelerated filer

Key Financials

Operating Income
$-387200000
↓ 213.5%
Revenue
$824.5M
↓ 1.6%
Gross Profit
$576.6M
↓ 1.5%
Shareholders' Equity
$368.0M
↓ 47.5%
Total Liabilities
$338.6M
↑ 3.7%
Cash & Equivalents
$149.6M
↑ 46.1%
Net Income
$-365900000
↓ 187.4%
Total Assets
$706.6M
↓ 31.2%

Recent SEC Filings

Form Type Filed Date Link
8-K 10/9/2026 View on SEC
4 9/22/2026 View on SEC
4 9/18/2026 View on SEC
4 9/17/2026 View on SEC
3 9/17/2026 View on SEC
8-K 9/16/2026 View on SEC
4 9/8/2026 View on SEC
SCHEDULE 13G 9/4/2026 View on SEC
4 8/17/2026 View on SEC
SCHEDULE 13G/A 8/14/2026 View on SEC

Company Information

Field Value
Ticker MYGN
Company Name MYRIAD GENETICS INC
CIK 899923
Sector In Vitro & In Vivo Diagnostic Substances
Industry Accelerated filer
Exchange Nasdaq
SIC Code 2835
SIC Description In Vitro & In Vivo Diagnostic Substances
Entity Type operating
Fiscal Year End 1231
State of Incorporation DE
Phone 801-584-3600